Gene expression profiling and clinical outcome in melanoma: In search of novel prognostic factors

Expert Review of Anticancer Therapy

Volumn 7, Issue 11, 2007, Pages 1611-1631

  Winnepenninckx, Véronique ^a   van den Oord, Joost J ^b,c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Morphology and Molecular Pathology Section   (Belgium)

Author keywords

Gene expression; Immunohistochemistry; Melanoma; Microarray; Profiling; rognosis; Ttumor progression

Indexed keywords

ATORVASTATIN; BASIC FIBROBLAST GROWTH FACTOR; CATHEPSIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KI 67 ANTIGEN; MELAN A; MELANOMA ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN; MINICHROMOSOME MAINTENANCE PROTEIN 3; MINICHROMOSOME MAINTENANCE PROTEIN 4; MINICHROMOSOME MAINTENANCE PROTEIN 6; MYC PROTEIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100; RAS PROTEIN; RESVERATROL; SERINE PROTEINASE; SORAFENIB; SURVIVIN; VALPROIC ACID; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 3;

ACCURACY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TARGETING; FOLLOW UP; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOHISTOCHEMISTRY; MELANOMA; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; RADIATION EXPOSURE; REVIEW; TUMOR GROWTH; TUMOR VOLUME; ULTRAVIOLET RADIATION; UNINDEXED SEQUENCE;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 37349102704     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.11.1611     Document Type: Review

References (74)

1. Bishop DT, Demenais F, Goldstein AM et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J. Natl Cancer Inst. 94(12), 894-903 (2002).
2. Wachsmuth RC, Harland M, Bishop JA. The atypical-mole syndrome and predisposition to melanoma. N. Engl. J. Med. 339(5), 348-349 (1998).
3. Lew RA, Sober AJ, Cook N, Marvell R, Fitzpatrick TB. Sun exposure habits in patients with cutaneous melanoma - a case control study. J. Dermatol. Surg. Oncol. 9(12), 981-986 (1983).
4. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 22(20), 3099-3112 (2003).
5. Clark WH Jr, Elder DE, Guerry D, Epstein MN, Greene MH, Van HM. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15(12), 1147-1165 (1984).
6. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19(16), 3622-3634 (2001).
7. Clark WH Jr, Elder DE, Guerry D et al. Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81(24), 1893-1904 (1989).
8. Balch CM, Sober AJ, Soong SJ, Gershenwald JE. The new melanoma staging system. Semin. Cutan. Med. Surg. 22(1), 42-54 (2003).
9. Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol. 38(5), 535-547 (1999).
10. Spatz A, Gimotty PA, Cook MG et al. Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: an EORTC Melanoma Group study. J. Clin. Oncol. 25(Suppl. 18), 8519 (2007).
11. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant melanoma. Arch. Pathol. Lab. Med. 125(10), 1295-1306 (2001).
12. Hauschild A, Michaelsen J, Brenner W et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res. 9(2), 155-161 (1999).
13. Djukanovic D, Hofmann U, Sucker A, Rittgen W, Schadendorf D. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Anticancer Res. 20(3B), 2203-2206 (2000).
14. Banfalvi T, Gilde K, Boldizsar M et al. Serum concentration of 5-S-cysteinyldopa in patients with melanoma. Eur. J. Clin. Invest. 30(10), 900-904 (2000).
15. Boyano MD, Garcia-Vazquez MD, Lopez-Michelena T et al. Soluble interleukin-2 receptor, intercellular adhesion molecule-1 and HS interleukin-10 serum levels in patients with melanoma. Br. J. Cancer 83(7), 847-852 (2000).
16. Hoon DS, Bostick P, Kuo C et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 60(8), 2253-2257 (2000).
17. Moretti S, Spallanzani A, Chiarugi A, Fabiani M, Pinzi C. Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J. Am. Acad. Dermatol. 44(2), 188-192 (2001).
18. Gimotty PA, Van BP, Elder DE et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J. Clin. Oncol. 23(31), 8048-8056 (2005).
19. Kesmodel SB, Karakousis GC, Botbyl JD et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann. Surg. Oncol. 12(6), 449-458 (2005).
20. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev. 18(3), 345-357 (1999).
21. Ranuncolo SM, Ladeda V, Gorostidy S et al. Expression of CD44s and CD44 splice variants in human melanoma. Oncol. Rep. 9(1), 51-56 (2002).
22. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: assessment by the use of tissue microarray. Int. J. Cancer 118(6), 1460-1464 (2006).
23. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F. Wasson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast. Reconstr. Surg. 115 (2), 367-375 (2005).
24. Natali P, Nicotra MR, Cavaliere R et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res. 50(4), 1271-1278 (1990).
25. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res. 61(9), 3819-3825 (2001).
26. Sanders DS, Blessing K, Hassan GA, Bruton R, Marsden JR, Jankowski J. Alterations in cadherin and catenin expression during the biological progression of metanocytic tumors. Mol. Pathol. 52(3), 151-157 (1999).
27. Ferrier CM, Suciu S, van Geloof WL et al. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br. J. Cancer 83(10), 1351-1359 (2000).
28. Vaisanen A, Kallioinen M, von Dickhoff K, Laatikainen L, Hoyhtya M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma? J. Pathol. 188(1), 56-62 (1999).
29. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am. J. Pathol. 151(3), 665-670 (1997).
30. Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G. Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancet 91(5), 972-982 (2001).
31. van den Oord JJ, Vandeghinste N, De Ley M, de Wolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am. J. Pathol. 145(2), 294-300 (1994).
32. Grover R, Wilson GD. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Sug. Oncol. 22(4), 347-349 (1996).
33. Gradilone A, Gazzaniga P, Ribuffo D et al. Survivin, bcl-2, bax, and bcl-X gene expression in sentinel lymph nodes from melanoma patients. J. Clin. Oncol. 21(2), 306-312 (2003).
34. Rofstad EK, Halsor EF. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60(17), 4932-4938 (2000).
35. Barnhill RL, Busam KJ, Berwick M et al. Tumor vascularity is not a prognostic factor for cutaneous melanoma. Lancet 344(8931), 1237-1238 (1994).
36. Dadras SS, Lange-Asschenfeldt B, Velasco P et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod. Pathol. 18(9), 1232-1242 (2005).
37. Salti GI, Manougian T, Farolan M et al. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 60(18), 5012-5016 (2000).
38. van den Oord JJ, Maes A, Stas M et al. CD40 is a prognostic marker in primary cutaneous malignant melanoma. Am. J. Pathol. 149(6), 1953-1961 (1996).
39. Demunter A, Ahmadian MR, Libbrecht L et al. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res. 61(12), 4916-4922 (2001).
40. Rodolfo M, Daniotti M, Valiacchi V. Genetic progression of metastatic melanoma. Cancer Lett. 214(2), 133-147 (2004).
41. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 22(58), 9217-9224 (2003).
42. Houben R, Becker JC, Kappel A, Terheyden P, Brocker EB, Goetz R et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J. Carcinog. 3(1), 6 (2004).
43. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res.. 10(5), 1753-1757 (2004).
44. Ross DA, Wilson GD. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma. Br. J. Surg. 85(1), 46-51 (1998).
45. Hussein MR, Haemel AK, Wood GS. p53-related pathways and the molecular pathogenesis of melanoma. Eur. J. Cancer Prev. 12(2), 93-100 (2003).
46. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for Rho-C. Nature 406(6795), 532-535 (2000).
47. Carr KM, Bittner M, Trent JM. Gene-expression profiling in human. cutaneous melanoma. Oncogene 22(20), 3076-3080(2003).
48. de Wit NJ, Rijntjes J, Diepstra JH et al. Analysis of differential gene expression in human melanocytic tumor lesions by custom made oligonucleotide arrays. Br. J. Cancer 92(12), 2249-2261 (2005).
49. Baldi A, Battista T, De Luca A et al. Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp. Dermatol. 12(2), 213-218 (2003).
50. Brem R, Hildebrandt T, Jarsch M, van Muijen GN, Weidle UH. Identification of metastasis-associated genes by transcriptional profiling of a metastasizing versus a non-metastasizing human melanoma cell line. Anticancer Res. 21(3B), 1731-1740 (2001).
51. Hoek K, Rimm, DL, Williams KR et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res. 64(15), 5270-5282(2004).
52. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540 (2000).
53. Wang E, Miller LD, Ohnmacht GA et al. Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62(13), 3581-3586 (2002).
54. Winnepenninckx V, Lazar V, Michiels S et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst. 98, 472-482 (2006)
55. Kaufmann WK, Nevis KR, Qu P et al. Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. J. Invest. Dermatol. (2007) (Epub ahead of print).
56. Blagosklonny MV, An WG, Menno G, Nguyen F, Trepel JB, Neckers LM. Regulation of BRCA1 by protein degradation. Oncogene 18, 6460-6468 (1999).
57. Mukherjee G, Muralidhar B, Bafna UD, Laskey RA, Coleman N. MCM immunocytochemistry as a first line cervical screening test in developing countries: a prospective cohort study in a regional cancer centre in India. Br. J. Cancer 96, 1107-1111 (2007).
58. Lee C, Hong B, Choi JM et al. Structural basis for inhibition of the replication licensing factor Cdt1 by geminin. Nature 430, 913-917 (2004).
59. Gonzalez MA, Tachibana KE, Laskey RA, Coleman N. Control of DNA replication and its potential clinical exploitation. Nat. Rev. Cancer 5, 135-141 (2005).
60. De Snoo FA, Hayward NK. Cutaneous melanoma susceptibility and progression genes. Cancer Lett. 230, 153-186 (2005).
61. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 23, 4014-4022 (2004).
62. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijama T. Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islandsin putative promoter regions in human malignant melanomas. Cancer Res. 66, 6080-6086 (2006).
63. Fargeas CA, Florek M, Huttner WB, Corbeil D. Characterization of prominin-2, a new member of the prominin family of pentaspan membrane glycoproteins. J. Biol. Chem. 278, 8586-8596 (2003).
64. Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 64, 67-74 (2005).
65. Su B, Guan M, Xia J, Lu Y. Stimulation of lipocalin-type prostaglandin D synthase by retinoic acid coincides with inhibition of cell proliferation in human 3AO ovarian cancer cells. Cell Biol. Int. 27, 587-592 (2003).
66. Bild AH, Potti A, Nevins JR. Linking oncogenic pathways with therapeutic opportunities. Nat. Rev. Cancer 6, 735-741 (2006).
67. Collisson EA, Kleer C, Wu M et al. Atorvastatin prevents Rho-C isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther. 2, 941-948 (2003).
68. Liu T, Brouha B, Grossman D. Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 23, 39-48 (2004).
69. Pennati M, Binda M, De Cesare M et al. Ribozyme-mediated downregulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 25, 1129-1136 (2004).
70. Zhu ZB, Makhija SK, Lu B et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 11, 256-262 (2004).
71. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24, 2783-2784 (2004).
72. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl. J. Med. 353, 2135-2147 (2005).
73. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent, apoptosis in melanoma cells. Cancer Res. 66, 1611-1619 (2006).
74. Qin JZ, Ziffra J, Stennett L et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 65, 6282-6293 (2005).